On-Demand: The Hitchhiker’s Guide to CGTx in 2023

2023-01-30T14:52:17-05:00Cell & Gene Therapy, Events|

Cell & gene therapy advancement has increased at an immense rate over the past decade. With the right tools and guidance, patients can receive new forms of treatments. Staying up to date with progress in the field is as important as ever with the constant strive to improve technology, especially in areas like regulatory pathways, novel technologies, and CMC and manufacturing trends.

Sponsored by Precision ADVANCE, this Life Science Connect webinar will convene leading advanced therapy experts to discuss innovation and expectations for advanced therapies in 2023. This discussion will be moderated by Andy Kinley (VP of Innovation & Clinical Science, Precision for Medicine), and include insights from Peter Andersen (CSO, Vita Therapeutics), Deb Phippard (CSO, Precision for Medicine), Palani Palaniappan (CTO, Flagship Pioneering), Phil Cyr (SVP, Precision Value & Health), and Charlie Harper (VP, Project Farma).


On-Demand: State of the Union for Advanced Medicines

2022-12-05T15:00:44-05:00Cell & Gene Therapy|

Regenerative medicines are evolving at breakneck speed—and every advance has far-reaching implications. To be effective in CGTx development, you also need to understand the current investment landscape, new and exciting technologies, and the latest progress in drug development, manufacturing, regulatory, and reimbursement.

Sponsored by Precision ADVANCE, this Endpoints webinar with convene leading advanced therapy experts to discuss how to be effective in CGTx development. This discussion will be moderated by Anshul Mangal (President, Project Farma & Precision ADVANCE), and include insights from Phil Cyr (EVP, Precision Value & Health), David Greenwald (VP of Business Development, Deerfield Management), Rajul Jain (Managing Director, Vida Ventures), Joseph La Barge (CEO, Apertura Gene Therapy), and Adrian Woolfson (Executive Chairman, President & Co-Founder, Replay Bio).


On-Demand: Overcoming Manufacturing Challenges for Advanced Medicines

2022-11-03T10:27:15-04:00Cell & Gene Therapy, Events|

Sponsored by Precision ADVANCE, this Endpoints webinar with convene leading advanced therapy experts to discuss manufacturing strategies for next-generation medicines. This discussion will be moderated by Adam Pfeiffer (VP of Strategy, Project Farma), and include insights from Charlie Harper (VP, Project Farma), Brian Stamper (VP of Cell Therapy Operations, Immunomic Therapeutics Inc.), Jim Watson (VP, Project Farma), Brian Riley (Chief Manufacturing Officer, Beam Therapeutics), and Chad Salisbury (SVP, Project Farma).


On-Demand: Gene Therapy Roundup—What to know now from the lab to the FDA

2022-11-02T15:59:47-04:00Cell & Gene Therapy, Events|

Gene therapy continues to evolve rapidly – from the science to the regulatory requirements. To give you a greater perspective on recent developments, this panel discussion brings together gene therapy experts across assay development, regulatory submissions, and clinical trial strategy who will share observations from the front lines on a multitude of gene therapy and rare disease projects.


On Demand: Cell & Gene Day

2022-12-19T13:48:20-05:00Cell & Gene Therapy, Events, Thought Leadership|

As a wave of up-and-coming cell and gene therapies eye the path to approval soon, a combination of uncertainties threatens the waters ahead. A lack of talent, shortage of manufacturing, standardization, and shifting infrastructure are just the beginning of a range of potential issues.

Join Endpoints News and Precision ADVANCE for Cell & Gene Day, a free virtual event on August 24, from 12:00-4:00 PM ET where we convene three distinguished panels of experts to find out where the field stands today and explore funding, development and launch strategies to smooth out the ride to commercialization. You will hear from successful innovators from each facet of the CGTx landscape, including executives from Blackstone, Flagship Pioneering, Monograph Capital, Alliance for Regenerative Medicine, Satellite Bio, Cellevolve Bio, and more.

Publication: Rare Disease on Payer’s Minds

2022-06-30T11:43:35-04:00Cell & Gene Therapy, Thought Leadership|

As payers began to deal with increased costs in 2021 due to deferred care during the COVID-19 pandemic, they still continued to grapple with the prospect of the impact of future gene therapies’ cost, according to industry experts. Precision’s Phil Cyr (SVP) and Erin Lopata (VP, Access Experience Team) weigh in on new ways to pay for the potential flood of gene therapies for rare diseases brewing in the pipeline.


Load More Posts